TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
【主な結果】
* Median progression-free survival
2·6 months (95% CI 1·6-3·5) in the TAS-102 group
4·6 months (3·5-6·5) in the TAS-102 plus bevacizumab group
Hazard ratio 0·45 (95% CI 0·29-0·72); p=0·0015